| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Leo Pharma prepares to come for the topical JAK market as Incyte's Opzelura cream launch cools off | 4 | FiercePharma | ||
| Mi | Incyte Corporation (INCY) Q1 2024 Earnings Call Transcript | 8 | Insider Monkey | ||
| Di | INCYTE CORP - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| Di | Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates | 5 | Zacks | ||
| Di | Incyte misses quarterly profit on weak sales of lead drug | 6 | Reuters | ||
| Di | Incyte Corp falls on lower-than-expected revenue, profit | 3 | Reuters | ||
| Di | Incyte Corporation Q1 Profit Increases, but misses estimates | 217 | AFX News | WASHINGTON (dpa-AFX) - Incyte Corporation (INCY) revealed earnings for its first quarter that increased from last year but missed the Street estimates.The company's bottom line totaled $169.548... ► Artikel lesen | |
| Di | Incyte shares dip after earnings, guidance miss | 4 | Investing.com | ||
| Di | Incyte: EPS verfehlt Schätzungen um 0,18 $ - Umsatz schlechter als erwartet | 8 | Investing.com Deutsch | ||
| Di | Incyte earnings missed by $0.18, revenue fell short of estimates | 4 | Investing.com | ||
| Di | INCYTE CORP - 8-K, Current Report | 2 | SEC Filings | ||
| Di | Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs | 72 | Business Wire | WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today reports 2024 first quarter financial results, and provides a status update on the Company's clinical development portfolio.
"In... ► Artikel lesen | |
| Mo | Incyte Q1 2024 Earnings Preview | 9 | Seeking Alpha | ||
| 26.04. | Incyte Corp expected to post earnings of 84 cents a share - Earnings Preview | 11 | Reuters | ||
| 24.04. | Incyte announces agreement to acquire Escient Pharmaceuticals for $750m | 8 | PMLiVE | ||
| 24.04. | Incyte signs deal to acquire Escient Pharmaceuticals | 3 | Pharmaceutical Technology | ||
| 24.04. | Incyte and Escient Pharmaceuticals: Incyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekannt | 310 | Business Wire | EP262, ein oraler First-in-Class-Antagonist des Mas-verwandten, G-Protein-gekoppelten Rezeptors X2 (MRGPRX2) mit dem Potenzial zur Behandlung eines breiten Spektrums entzündlicher Erkrankungen... ► Artikel lesen | |
| 24.04. | Incyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekannt | 57 | Business Wire | WILMINGTON, Delaware, und SAN DIEGO, Kalifornien, USA--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) und Escient Pharmaceuticals - ein Unternehmen, das auf die klinische Phase der Arzneimittelforschung... ► Artikel lesen | |
| 23.04. | Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends | 6 | Benzinga.com | ||
| 23.04. | Peeling Back The Layers: Exploring Incyte Through Analyst Insights | 3 | Benzinga.com |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 2.741 |
| NEL | 1.604 |
| APPLE | 1.482 |
| BYD | 1.427 |
| BAYER | 1.417 |
| SUPER MICRO COMPUTER | 1.318 |
| DEUTSCHE BANK | 1.206 |
| TUI | 1.178 |
| NVIDIA | 1.173 |
| PLUG POWER | 1.032 |
| TESLA | 975 |
| DAIMLER TRUCK | 922 |
| MERCEDES-BENZ | 885 |
| RWE | 864 |
| RHEINMETALL | 863 |
| AURUBIS | 784 |
| RENK GROUP | 766 |
| DEUTSCHE LUFTHANSA | 748 |
| VOLKSWAGEN | 741 |
| COMMERZBANK | 738 |
| AMAZON | 717 |
| SIEMENS ENERGY | 671 |
| AIXTRON SE | 645 |
| SIXT SE VZ | 636 |
| BASF | 593 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
